ÂÜÀòÂÒÂ×

Gene Merutka has a strong background in CMC development and regulatory affairs. Gene is currently the Head of CMC at Sapience Therapeutics, Inc. Since 2016, they have also been the President of Merutka Pharmaceutical Consulting, where they provide consulting services in CMC development and regulatory affairs, with expertise in peptide therapeutics and alternative drug delivery methods. Prior to that, they were the Co-Founder and Senior VP Development at Merganser Biotech, Inc. from 2011 to 2016. Gene also held senior positions at Azelon Pharmaceuticals, Vicuron Pharmaceuticals, IntraBiotics Pharmaceuticals, Trimeris, and The Scripps Research Institute.

Gene Merutka received their Bachelor of Science degree in Chemistry from the University of Chicago, where they studied from 1981 to 1985. Later, they pursued postgraduate studies at the University of Iowa, specializing in Biochemistry to obtain their Ph.D. However, no specific start or end year was provided for their time at the University of Iowa.